Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease
Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…Dyskinesia, Pain, and Quality of Life in Parkinson’s Disease: Post Hoc Analysis From the DYSCOVER Study
Objective: Evaluate correlations between dyskinesia, health-related quality of life (HRQoL), activities of daily living (ADL), and pain in patients with advanced Parkinson’s disease (PD) who…Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism
Objective: We set out to compare patterns of dyskinetic behaviours induced by the systemic administration of L-DOPA and D1 or D2 receptor (D1R, D2R) agonists…Wearable sensor motor outcomes across patients with Parkinson’s disease from Asian, Black, and Caucasian ethnicity in the United Kingdom
Objective: To determine the effect of ethnic background on motor scores in people with Parkinson’s disease (PwP) using objective measurement. Background: Limited evidence has suggested…The influence of culture on the relationship between subjective and objective assessments of dyskinesia severity.
Objective: To explore the relationship and rate of agreement between patient and clinician evaluation of dyskinesia severity and impact on function across multiple cultures. Background:…A Case of Autoimmune Orofacial Dyskinesia associated with Striational Antibody
Objective: This is a case of steroid-responsive, autoimmune orofacial dyskinesia associated with extremely elevated striational [striated muscle] antibody. We present this instructive case to add…Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)
Objective: To identify, characterize and treat dyskinesias and off time in a patient with PD via the use of gamma and beta peak LFP using…Deep brain stimulation of the pallidofugal pathways to rescue severe brittle dyskinesias after STN-DBS lead implantation
Objective: To present a case with a severe life-threatening microlesion effect related with STN DBS rescued with a tractography-guided neuromodulation approach Background: Microlesion effect have…Hyperkinetic Movement Disorders after Thalamic Lesions
Objective: To describe delayed hyperkinetic movement disorder after a thalamic lesion. Background: Lesions in the basal ganglia circuit can cause abnormal movement disorders. After thalamic…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 40
- Next Page »